168 related articles for article (PubMed ID: 7840511)
21. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.
Foekens JA; van Putten WL; Portengen H; Rodenburg CJ; Reubi JC; Berns PM; Henzen-Logmans SC; van der Burg ME; Alexieva-Figusch J; Klijn JG
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):815-21. PubMed ID: 2178364
[TBL] [Abstract][Full Text] [Related]
23. pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status.
Looi LM; Azura WW; Cheah PL; Ng MH
Pathology; 2001 Aug; 33(3):283-6. PubMed ID: 11523925
[TBL] [Abstract][Full Text] [Related]
24. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy.
Predine J; Spyratos F; Prud'homme JF; Andrieu C; Hacene K; Brunet M; Pallud C; Milgrom E
Cancer; 1992 Apr; 69(8):2116-23. PubMed ID: 1544118
[TBL] [Abstract][Full Text] [Related]
25. pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer.
Jansen RL; Hupperets PS; Arends JW; Joosten-Achjanie SR; Volovics A; Hillen HF; Schouten HC
Anticancer Res; 1998; 18(1B):577-82. PubMed ID: 9568180
[TBL] [Abstract][Full Text] [Related]
26. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
MacGrogan G; Mauriac L; Durand M; Bonichon F; Trojani M; de Mascarel I; Coindre JM
Br J Cancer; 1996 Nov; 74(9):1458-65. PubMed ID: 8912545
[TBL] [Abstract][Full Text] [Related]
27. PS2 protein in breast carcinomas: cut-off value of estrogen-regulated expression.
Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Nesković-Konstantinović Z; Branković-Magić M
Neoplasma; 2001; 48(1):1-6. PubMed ID: 11327531
[TBL] [Abstract][Full Text] [Related]
28. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
[TBL] [Abstract][Full Text] [Related]
30. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
[TBL] [Abstract][Full Text] [Related]
31. Biochemical parameters for prognostic evaluation in patients with breast cancer.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
[TBL] [Abstract][Full Text] [Related]
32. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
33. [Clinico-biological impact of pS2 positivity in estrogen receptor negative-infiltrating ductal carcinomas of the breast].
Ruibal A; Arias J; del Río MC; San Román JM; Lapeña G; Pardo C; Tejerina A
Rev Esp Med Nucl; 2000 Oct; 19(6):428-33. PubMed ID: 11060273
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours.
Pallud C; Le Doussal V; Pichon MF; Prud'homme JF; Hacene K; Milgrom E
Histopathology; 1993 Sep; 23(3):249-56. PubMed ID: 8225243
[TBL] [Abstract][Full Text] [Related]
36. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
[TBL] [Abstract][Full Text] [Related]
37. Expression of pS2 protein in breast cancer.
Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ
Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
[TBL] [Abstract][Full Text] [Related]
39. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
Ruibal A; Garrido-Pumar M; Arias JI
Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
[TBL] [Abstract][Full Text] [Related]
40. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
